IGC Pharma, Inc. (IGC) P/E Ratio History
Deep ValueTrading at -3.7x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2007–2008
Loading P/E history...
P/E Ratio Analysis
As of June 29, 2026, IGC Pharma, Inc. (IGC) trades at a price-to-earnings ratio of -3.7x, with a stock price of $0.27 and trailing twelve-month earnings per share of $-0.07.
The current P/E is 102% below its 5-year average of 156.0x. Over the past five years, IGC's P/E has ranged from a low of 45.3x to a high of 476.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, IGC trades at a 116% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, IGC trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our IGC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
IGC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
IGC P/E vs Peers
Neuroscience and Psychiatry Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 16.0 | 4.28 | -29% | |
| $449M | 33.0 | 0.99Best | +51% | |
| $1B | 3.5Lowest | - | +307%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
IGC Historical P/E Data (2007–2008)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2008 Q3 | Dec 31 2007 | $59.00 | $0.12 | 476.2x | +205% |
| FY2008 Q2 | Sep 30 2007 | $58.50 | $0.46 | 126.1x | -19% |
| FY2008 Q1 | Jun 30 2007 | $57.40 | $0.76 | 75.9x | -51% |
| FY2007 Q4 | Mar 31 2007 | $58.40 | $1.03 | 56.7x | -64% |
| FY2007 Q3 | Dec 31 2006 | $58.40 | $1.29 | 45.3x | -71% |
Average P/E for displayed period: 156.0x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IGC — Frequently Asked Questions
Quick answers to the most common questions about buying IGC stock.
What is IGC's P/E ratio?
IGC Pharma, Inc. (IGC) trailing twelve-month P/E ratio is -3.7x, based on TTM diluted EPS of $-0.07. The 5-year average P/E is 156.0x and the historical range spans 45.3x to 476.2x.
Is IGC stock overvalued or undervalued?
IGC trades at -3.7x P/E, below its 5-year average of 156.0x. At the 0th percentile of its historical range (45.3x–476.2x), the stock is priced at a discount to its own history.
Is IGC stock expensive?
No, IGC is not expensive on a historical basis. The current P/E of -3.7x is below the 5-year average of 156.0x and sits at the 0th percentile of its valuation range.
What is IGC's historical P/E range?
Over the past 5 years, IGC's P/E ratio has ranged from 45.3x to 476.2x, with a median of 75.9x and an average of 156.0x. The current P/E of -3.7x places the stock at the 0th percentile of this range. Full historical data spans 2007–2008.
How does IGC's P/E compare to the S&P 500?
IGC trades at -3.7x P/E versus the S&P 500 median of 25.3x. The 115% discount to the market suggests lower growth expectations or perceived higher risk.
How does IGC's valuation compare to Healthcare peers?
IGC Pharma, Inc. P/E of -3.7x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is IGC's PEG ratio?
IGC PEG ratio is N/A, based on a P/E of -3.7x and EPS growth of 22.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is IGC's earnings yield?
IGC earnings yield is N/A, the inverse of its -3.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.